Cargando…
Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors
LMB-100 is a mesothelin-targeted recombinant immunotoxin (iTox) that carries a modified Pseuodomonas exotoxin A (PE) payload. PE kills cells by inhibiting synthesis of new proteins. We found that treatment of pancreatic cancer cells with LMB-100 for 24–48 h did not change total protein level despite...
Autores principales: | El-Behaedi, Salma, Landsman, Rebekah, Rudloff, Michael, Kolyvas, Emily, Albalawy, Rakan, Zhang, Xianyu, Bera, Tapan, Collins, Keith, Kozlov, Serguei, Alewine, Christine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267581/ https://www.ncbi.nlm.nih.gov/pubmed/30384408 http://dx.doi.org/10.3390/toxins10110447 |
Ejemplares similares
-
Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes
por: Kolyvas, Emily, et al.
Publicado: (2016) -
Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel
por: Pegna, Guillaume Joe, et al.
Publicado: (2022) -
Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors
por: Hagerty, Brendan L., et al.
Publicado: (2020) -
Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment
por: Zhang, Xianyu, et al.
Publicado: (2022) -
Combining anti-CTLA4 with RG7787, an immunotoxin targeting mesothelin, promotes tumor eradication
por: Leshem, Jasmin, et al.
Publicado: (2015)